Protalex Inc (PRTX) 5.6400 $PRTX
Protalex Announces Findings from Final Cohort of U.S. Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Thu Apr 16, 7:30AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, announced that it has completed analysis from the final cohort (Cohort 5) of its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA; the 104 Study). PRTX-100, Protalex's lead drug, is a highly purified form of Staphylococcal Protein A, which is the subject of ongoing clinical development in rheumatoid arthritis RA. Under a separate Investigational New Drug application, the Company will soon commence a clinical trial of PRTX-100 in patients suffering from chronic Immune Thrombocytopenia (ITP), an orphan disease.
Protalex To Start Phase 1/2 Trial With PRTX-100 In Patients With ITP
Jason Napodano, CFA - at Seeking Alpha - Tue Apr 07, 1:38PM CDT
Protalex Announces FDA Acceptance of Investigational New Drug Application for PRTX-100 to Treat Immune Thrombocytopenia
Business Wire - Tue Mar 31, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced today that it has received notice from the Office of Hematology and Oncology Products of the U.S. Food and Drug Administration (FDA) that it has reviewed the Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for PRTX-100 and concluded that clinical studies with PRTX-100 in patients with Immune Thrombocytopenia (ITP) may be initiated. PRTX-100, Protalex's lead drug, is a highly purified form of Staphylococcal Protein A and is the subject of ongoing clinical development in rheumatoid arthritis (RA) under a separate IND previously submitted to the FDA's Division of Pulmonary, Allergy, and Rheumatology Products.
Protalex Initiates Enrollment of Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Thu Mar 12, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced today that following completion of its U.S.-based, multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 (the 104 Study) in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA), the Company has initiated enrollment of a Phase I/II open-label, multiple, fixed-dose study (the 105 Study) that is open only to 104 Study patients who indicated their desire for additional treatment. Protalex's lead drug PRTX-100 is a highly purified form of Staphylococcal Protein A.
Protalex Aiming At Rheumatoid Arthritis Market With A Much Cheaper Price Tag
EricFinance - at Seeking Alpha - Fri Jan 30, 11:13AM CST
JNJ: 102.30 (+0.47), AMGN: 162.36 (+0.38), ABBV: 65.99 (+0.02), REGN: 489.01 (-2.42)
Next Steps For Protalex With PRTX-100 Expected To Unlock Significant Value
Jason Napodano, CFA - at Seeking Alpha - Wed Jan 21, 11:43AM CST
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 41.63 (-0.31), NVIV: 13.06 (+0.31), LPCN: 7.66 (-0.04), EPRS: 5.61 (-0.14), DEPO: 20.54 (+0.52), ASPX: 100.96 (unch), BCLI: 3.66 (-0.04), CUR: 1.70 (-0.04)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 10.01 (+0.09), VTAE: 12.76 (-0.23), XNCR: 15.32 (+0.38)
Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Treated for Longer Duration Shows Safety and Reduction in Disease Activity
Business Wire - Mon Nov 17, 8:15AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced that data highlighting results from Cohorts 1 through 5 of its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA; the PRTX-100-104 Study) were presented today at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014, underway in Boston. The poster is now available on the Company's website at www.protalex.com.
Protalex to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Thu Sep 04, 3:05PM CDT
Protalex, Inc. (OTCBB RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw Annual Global Investment Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City.
Protalex Announces Acceptance of Abstract Highlighting Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 American College of Rheumatology Annual Meeting
Business Wire - Wed Sep 03, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was accepted for poster presentation at the upcoming American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014 being held in Boston, Massachusetts from November 14-19, 2014. The abstract will be available at the ACR's website at http://www.acrannualmeeting.org and on the Company's website at www.protalex.com.
Protalex Announces Data from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients Presented at the 2014 EULAR Annual European Congress of Rheumatology
Business Wire - Fri Jun 13, 5:30AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR's Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR's website at www.eular.org and the complete poster is available on the Company's website at www.protalex.com.
Protalex Announces Findings from Final Cohort of U.S. Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Thu Apr 16, 7:30AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, announced that it has completed analysis from the final cohort (Cohort 5) of its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA; the 104 Study). PRTX-100, Protalex's lead drug, is a highly purified form of Staphylococcal Protein A, which is the subject of ongoing clinical development in rheumatoid arthritis RA. Under a separate Investigational New Drug application, the Company will soon commence a clinical trial of PRTX-100 in patients suffering from chronic Immune Thrombocytopenia (ITP), an orphan disease. Protalex To Start Phase 1/2 Trial With PRTX-100 In Patients With ITP
Jason Napodano, CFA - at Seeking Alpha - Tue Apr 07, 1:38PM CDT
Protalex Announces FDA Acceptance of Investigational New Drug Application for PRTX-100 to Treat Immune Thrombocytopenia
Business Wire - Tue Mar 31, 7:00AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, announced today that it has received notice from the Office of Hematology and Oncology Products of the U.S. Food and Drug Administration (FDA) that it has reviewed the Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for PRTX-100 and concluded that clinical studies with PRTX-100 in patients with Immune Thrombocytopenia (ITP) may be initiated. PRTX-100, Protalex's lead drug, is a highly purified form of Staphylococcal Protein A and is the subject of ongoing clinical development in rheumatoid arthritis (RA) under a separate IND previously submitted to the FDA's Division of Pulmonary, Allergy, and Rheumatology Products. Protalex Initiates Enrollment of Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Thu Mar 12, 7:00AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, announced today that following completion of its U.S.-based, multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 (the 104 Study) in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA), the Company has initiated enrollment of a Phase I/II open-label, multiple, fixed-dose study (the 105 Study) that is open only to 104 Study patients who indicated their desire for additional treatment. Protalex's lead drug PRTX-100 is a highly purified form of Staphylococcal Protein A. Protalex Aiming At Rheumatoid Arthritis Market With A Much Cheaper Price Tag
EricFinance - at Seeking Alpha - Fri Jan 30, 11:13AM CST
JNJ: 102.30 (+0.47), AMGN: 162.36 (+0.38), ABBV: 65.99 (+0.02), REGN: 489.01 (-2.42)
Next Steps For Protalex With PRTX-100 Expected To Unlock Significant Value
Jason Napodano, CFA - at Seeking Alpha - Wed Jan 21, 11:43AM CST
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 41.63 (-0.31), NVIV: 13.06 (+0.31), LPCN: 7.66 (-0.04), EPRS: 5.61 (-0.14), DEPO: 20.54 (+0.52), ASPX: 100.96 (unch), BCLI: 3.66 (-0.04), CUR: 1.70 (-0.04)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 10.01 (+0.09), VTAE: 12.76 (-0.23), XNCR: 15.32 (+0.38)
Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Treated for Longer Duration Shows Safety and Reduction in Disease Activity
Business Wire - Mon Nov 17, 8:15AM CST
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, announced that data highlighting results from Cohorts 1 through 5 of its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA; the PRTX-100-104 Study) were presented today at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014, underway in Boston. The poster is now available on the Company's website at www.protalex.com. Protalex to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Thu Sep 04, 3:05PM CDT
Protalex, Inc. (OTCBB
RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw Annual Global Investment Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. Protalex Announces Acceptance of Abstract Highlighting Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 American College of Rheumatology Annual Meeting
Business Wire - Wed Sep 03, 7:00AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was accepted for poster presentation at the upcoming American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014 being held in Boston, Massachusetts from November 14-19, 2014. The abstract will be available at the ACR's website at http://www.acrannualmeeting.org and on the Company's website at www.protalex.com. Protalex Announces Data from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients Presented at the 2014 EULAR Annual European Congress of Rheumatology
Business Wire - Fri Jun 13, 5:30AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR's Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR's website at www.eular.org and the complete poster is available on the Company's website at www.protalex.com. 
